Cambridge, MA, United States of America

Joan Mannick

USPTO Granted Patents = 20 

 

 

Average Co-Inventor Count = 5.0

ph-index = 7

Forward Citations = 165(Granted Patents)


Location History:

  • Weston, MA (US) (2008 - 2021)
  • Cambridge, MA (US) (2017 - 2023)

Company Filing History:


Years Active: 2008-2025

Loading Chart...
Loading Chart...
Loading Chart...
20 patents (USPTO):

Title: Contributions of Joan Mannick in Cancer Treatment Innovations

Introduction: Joan Mannick is an esteemed inventor based in Cambridge, MA, with a notable portfolio of 20 patents. His innovative work primarily focuses on developing advanced therapies for cancer treatment, utilizing cutting-edge technologies in immunotherapy.

Latest Patents: Among his recent patents, two significant inventions stand out. The first is centered around the "Treatment of cancer using humanized anti-BCMA chimeric antigen receptor." This invention encompasses compositions and methods that target diseases linked to the expression of BCMA (B-cell maturation antigen). It includes the development of a chimeric antigen receptor (CAR) specific to BCMA, along with vectors encoding these receptors and recombinant T cells. Furthermore, it details methods for administering genetically modified T cells that express a CAR with a BCMA binding domain.

The second patent addresses the "Treatment of cancer using a CD123 chimeric antigen receptor." This invention similarly provides compositions and methods for targeting diseases associated with CD123 expression. It includes the formulation of a CD123-specific chimeric antigen receptor, corresponding vectors, and recombinant cells, along with procedures for delivering genetically modified cells that express a CAR with a CD123 binding domain.

Career Highlights: Joan Mannick has had an illustrious career, showcasing his expertise through his contributions to major healthcare organizations. He has notably worked with Novartis AG and the University of Pennsylvania, where his skills in research and development have propelled advancements in cancer therapies.

Collaborations: Throughout his career, Mannick has collaborated with esteemed colleagues such as David Jonathan Glass and Leon Murphy. These partnerships have culminated in significant innovations within the field of biomedicine, particularly in targeted cancer treatments.

Conclusion: Joan Mannick's dedication to cancer research and his impressive track record of patents illustrate his vital role in the advancement of immunotherapy. His contributions, particularly in developing chimeric antigen receptors, continue to influence the landscape of cancer treatment, showcasing the potential of innovative therapies in addressing complex medical challenges.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…